Trial Profile
A double-blind, double-dummy, parallel-group, placebo-controlled, randomized study to assess the duration of the suppressive effects of desloratadine on the cutaneous allergen-induced wheal and flare (1) response after discontinuation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Desloratadine (Primary) ; Levocetirizine
- Indications Allergic rhinitis; Hypersensitivity
- Focus Therapeutic Use
- Sponsors Organon
- 10 Nov 2006 New trial record.